Navigation Links
First Bellwether Trial in Multidistrict Litigation for DePuy Orthopaedics Inc.’s All-Metal Hip Implant to Commence on September 9 in Ohio’s Northern District, Reports Parker Waichman LLP
Date:8/30/2013

New York, New York (PRWEB) August 30, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective medical devices, notes that, according to court documents, U.S. District Judge David A. Katz, who is presiding over the DePuy ASR hip implant multidistrict litigation (MDL) in U.S. District Court, Northern District of Ohio, has ordered that the first bellwether trial’s start date remain September 9, 2013, even though an earlier Order had vacated what was originally supposed to be the first bellwether trial, the case of Dorney-Madgitz v. DePuy (Case No. 1:11 dp 20112). The start of the new initial trial, McCracken v. DePuy (Case No 1:11 dp 20485), remains September 9. The overall litigation is entitled: In Re DePuy Orthopaedics, Inc., ASR Hip Implant Products Liability Litigation (MDL 2197).

The Plaintiff, Ann McCracken, was implanted with the DePuy ASR metal hip on or around Aug. 24, 2009. According to the Complaint, she alleges that, as a result of the procedure, “she suffered and continues to suffer serious bodily injury and was forced to undergo revision surgery on or around Jan. 17, 2011,” according to court documents. McCracken resides in Rochester, New York.

“Revision surgery is a primary concern when metal-on-metal implants fail, so we are pleased to be less than two weeks away from the start date,” said Daniel C. Burke, Senior Litigation Counsel at Parker Waichman LLP. “Many implant patients will often require multiple revision surgeries. These procedures involve the surgeon replacing the hip implant and also repairing any bone and/or tissue damage caused by metal debris shed by the implant. Revision surgeries are of increasingly longer durations and entail increasingly lengthier rehabilitation periods. The high complication rate is a concern as well.”

The DePuy ASR and other metal-on-metal hip implants were approved without clinical testing for safety or efficacy due to the 510(k) approval route, which exempts devices from clinical testing as long as the manufacturers show that their product is similar to a previously approved device. The U.S. Food and Drug Administration (FDA) reported on Jan. 18, 2013, that it was attempting to change the 510(k) approval process; the agency has proposed that all-metal hip replacements go through premarket approval, which would require device makers to prove that their products are safe and effective.

The FDA, in that report, also advises people implanted with a metal hip to immediately speak with their doctors if they experience any of the following symptoms:

  •     Early failure, revision surgery
  •     Metallosis, high levels of metal ions in the bloodstream
  •     Difficulty walking, or a change in their ability to walk
  •     Swelling
  •     Pain

Johnson & Johnson, which owns DePuy as a subsidiary, recalled 93,000 ASR hips in 2010, citing a failure rate of 12 percent in five years, according to a March 8, 2013, Bloomberg report. In Australia, failure rates have exceeded 40 percent in seven years.

Parker Waichman LLP continues to offer free legal consultations to victims of DePuy ASR and other metal-on-metal hip implant injuries. If you or a loved one experienced premature failure of your implant or other health problems associated with a recalled DePuy ASR Hip Implant or other metal-on-metal hip implant, please contact their office by visiting the firm's DePuy ASR hip implant injury page at yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
1+ (800) LAW-INFO
1+ (800) 529-4636
http://www.yourlawyer.com

Read the full story at http://www.prweb.com/releases/DePuy_bellwether_starts/08/prweb11079571.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. First targeted nanomedicine to enter human clinical studies
2. First contact: Early intervention key in diagnosis and treatment of serious mental illness
3. Donor Kidney Re-Used in Second Patient After Failing in First
4. Many Who First Misuse Prescription Pills Get Them From Friends, Family: Report
5. First-of-its-kind Menopause Map helps women navigate treatment
6. First recipients of AcademyHealths Presidential Scholarship announced
7. Kessler Foundation researchers present at first International Congress on Cognition in MS
8. Whos the Dad? First-Trimester Blood Test May Tell
9. AGA releases first independently developed ABIM-approved Practice Improvement Module in GI
10. Dr. Yael Mosse will receive first Nachman Award in Pediatric Oncology at national conference
11. First study investigating possible link between sunscreen ingredient and endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 2016 , ... When it came time to blow out his candles on his 14th birthday, ... Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his family with a ... heart transplant recipient. , “He was playing at home, when we got the phone ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... services from offices located in South Lyon, Dewitt, Williamston, East Lansing, Ann Arbor, ... coach who needs treatment for a brain tumor. , Jason Bauer and his ...
(Date:12/7/2016)... ... 07, 2016 , ... Augustine Insurance Agency, a locally owned ... owners in the greater Dallas metropolitan area, is announcing a charity event that ... Established in 2009 by active police professionals in the Dallas region, the Dallas ...
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are giving back to ... fortunate enough to receive bountiful gifts wrapped tightly under a Christmas Tree. AlignLife ... children of the world. , In exchange for generous donations, customers will receive a ...
(Date:12/7/2016)... ... OCTOBER XX, 2016 (PRWEB) (PRWEB) December 07, 2016 , ... ... “Canine Filamentous Dermatitis Associated with Borrelia Infection” reveals that a condition ... in the prestigious Journal of Veterinary Science & Medical Diagnosis. , Morgellons disease ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016  Arcturus Therapeutics, Inc. ... company, announced today that it entered into collaboration ... therapeutics for the treatment of NASH and other ... delivery platform LUNAR™ and UNA Oligomer chemistry. The ... Takeda,s long-standing commitment to and expertise in GI ...
(Date:12/6/2016)... Dec. 6, 2016  Regulus Therapeutics Inc. (NASDAQ: ... the discovery and development of innovative medicines targeting ... at its R&D day, held in ... is an anti-miR targeting microRNA-27 (miR-27) for the ... is an anti-miR targeting microRNA-17 (miR-17) for the ...
(Date:12/6/2016)... new study released today by the Alliance for Integrity ... Pricing Program will continue to expand at an unprecedented rate ... $23 billion in total purchases at the 340B price. This ... B drug reimbursement purchases over the next five years.      ... data on total drug purchases through 340B from 2005 to ...
Breaking Medicine Technology: